Profit Margin (Quarterly) Chart

View Profit Margin (Quarterly) for GRFS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Profit Margin (Quarterly) Chart
Start Trial

Historical Profit Margin (Quarterly) Data

View and export this data back to 2006. Start Trial.
Date Value
June 30, 2026 9.77%
March 31, 2026 5.18%
December 31, 2025 6.35%
September 30, 2025 7.69%
June 30, 2025 7.32%
March 31, 2025 5.18%
December 31, 2024 4.24%
September 30, 2024 4.57%
June 30, 2024 1.36%
March 31, 2024 1.37%
December 31, 2023 4.42%
September 30, 2023 5.66%
June 30, 2023 4.57%
March 31, 2023 0.83%
March 31, 2021 12.74%
December 31, 2020 12.33%
September 30, 2020 21.12%
June 30, 2020 4.20%
March 31, 2020 15.74%
December 31, 2019 14.86%
September 30, 2019 11.55%
June 30, 2019 14.24%
March 31, 2019 9.88%
December 31, 2018 10.46%
September 30, 2018 12.99%
Date Value
June 30, 2018 15.95%
March 31, 2018 13.97%
December 31, 2017 21.59%
September 30, 2017 14.50%
June 30, 2017 12.70%
March 31, 2017 12.60%
December 31, 2016 12.66%
September 30, 2016 14.14%
June 30, 2016 14.03%
March 31, 2016 13.02%
December 31, 2015 12.32%
September 30, 2015 14.41%
June 30, 2015 13.38%
March 31, 2015 14.07%
December 31, 2014 14.24%
September 30, 2014 13.72%
June 30, 2014 12.71%
March 31, 2014 14.99%
December 31, 2013 11.24%
September 30, 2013 12.54%
June 30, 2013 13.04%
March 31, 2013 13.10%
December 31, 2012 8.96%
September 30, 2012 9.75%
June 30, 2012 10.14%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
Autolus Therapeutics Plc -85.60%
argenx SE --
Evaxion AS --
Akari Therapeutics Plc --
Pharma Mar SA -1.96%